Drug Discovery Market Analysis and Reports | Austria Conference Series

Market Analysis - Drug Discovery 2017

Organizing Committee is delighted to invite you to attend the 3rd International Conference and Expo on Drug Discovery & Designing, one of its remarkable Pharmaceutical conferences, to be held during September 25-27, 2017 in Vienna, Austria emphasizing on recent areas of more optimized research techniques like rational and computer aided drug designing for the Discovery, Designing and Development of new drugs than by traditional hit and trial method.

Drug Design is an impressive inventive process of new medication on the basis of biological target. Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is anticipated to reach around USD 6.5 billion by 2023.Drug Discovery  Informatics Market in U.S in million dollars. In 2012 total market for Drug Discovery Informatics was around in between 400 to 500 million, and is expected to reach around more than 3,500 million in 2022. Drug discovery is a complex process and represents a main component of the pharmaceutical industry. According to a new technical market research report, the global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%.The following graph showing global market for Drug Discovery technologies and products in billion between 2011 to 2017.

The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the biosimulation market.The global market of biomarkers was valued at USD 23.9 billion in 2015 and the global market of biomarkers is expected to reach $45.55 billion by 2020 from $23.9, and at a CAGR of 13.58% between 2015 and 2020. The increasing use of biomarkers for drug discovery and development coupled with high R&D expenditure is a major propelling factor for the market growth.We examine medicinal chemistry-related approaches and methodologies that drug discovery organizations employ in an effort to increase productivity in early drug discovery and decrease attrition at later pipeline stages. Key topics considered include structure-based drug design, fragment-based drug design, natural products-based drug design, diversity-oriented synthesis, and chemo genomics.In 2015, the global cancer immunotherapy market was valued at USD $37.50 billion, with its revenue expected to progress at a very strong CAGR of 14.6% with in a forecast period from 2016 to 2024, and the global cancer immunotherapy market is expected to reach USD $124.88 billion by the end of 2024. The Europe cancer immunotherapy market was worth $ 13.20 billion in 2016 and is estimated to reach $ 23.41 billion by the end of 2021 with growing potential of 12.45%.

Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. Monoclonal antibodies (mAbs) are remarkably versatile protein molecules with numerous applications in human health. More than 30 mAb therapeutics have been approved for marketing and approximately 360 mAbs are currently in clinical studies, with 30 in pivotal trials. The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024, a growth rate of 5.7% over the forecast period.

The global mass spectrometry market for the forecast  period of 2015 to 2020. This market is expected to reach USD 7,279.1 Million by 2020 from USD 4,919.9 in 2015 at a CAGR of 8.1% during the forecast period. The global spectroscopy market reached $13.5 billion in 2015 and should reach $15.6 billion in 2020, a compound annual growth rate (CAGR) of 2.9% through 2020. That "Near infrared emerged as the most widely used technology of process spectroscopy". The global proteomics market is projected to reach USD 21.87 Billion by 2021, at a CAGR of 11.7% from 2016 to 2021. The global proteomics market exhibits potential for significant growth and is propelled by the increasing need for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects. Pharmaceuticals represented a US$300 billion-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 billion by 2018.

Computer-aided drug design uses computational chemistry to discover, enhance, or study drugs and related biologically active molecules. The fundamental goal is to predict whether a given molecule will bind to a target and if so how strongly. CADD entails use of computing power to streamline drug discovery and development process, leverage of chemical and biological information about ligands and/or targets to identify and optimize new drugs, design of in silico filters to eliminate compounds with undesirable properties (poor activity and/or poor Absorption, Distribution, Metabolism, Excretion and Toxicity, ADMET) and select the most promising candidates.The global market for computational medicine and drug discovery software was estimated to be $5.2 billion in 2015 and is projected to escalate to $7.1 billion by 2021.

A number of factors such as increasing government spending on pharmaceutical R&D in emerging nations, rising focus on nanotechnology research, and continuous advancements in nanoparticle analysis technologies are fueling the demand of the nanoparticle analysis instruments. In addition, increasing application of nanotechnology in drug development and drug delivery processes, stringent regulatory guidelines for approval of medical products, and rising number of conferences and events leading to growing awareness about nanoparticle analysis technologies are some of the key factors offering new growth opportunities for existing market players as well as new entrants in the global nanoparticle analysis market. On the other hand, high cost of nanoparticle analysis instruments is one of the key factors hampering the growth of the nanoparticle analysis market. The global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%. The biggest increase will come in the area of drug delivery systems.

There is an impelling need to develop effective therapeutic strategies for patients with retinal disorders. From the past two decades on the mechanisms governing degeneration of the retina, it is now possible to devise innovative therapies based on retinal gene transfer. In gene transfer method we can correct the specific genetic defect in inherited retinal diseases, strategies to delay the onset of blindness independently of the disease-causing mutations and strategies to reactivate residual cells at late stages of the diseases. Under gene specific strategies like gene replacement for recessive inherited retinal disorder, gene-specific therapy for dominant inherited retinal disorders. Under non gene-specific therapies for ocular diseases mainly gene therapies modulating the secondary mechanisms of retinopathies, and  optogenetics. The global ophthalmic drugs market was valued at US$16 billion in 2012 and is estimated to reach a market value of US$21.6 billion by 2018, rising at a CAGR of 5.2% from 2013 to 2018.

New innovations in Drug Discovery

AstraZeneca shares world-leading world’s most advanced drug discovery robot through Open Innovation

NiCoLA-B, the world’s most advanced drug discovery robot, is teaming up with scientists from Cancer Research UK (CRUK) and the Medical Research Council (MRC), through AstraZeneca’s Open Innovation research collaboration program . The new robot, which can test up to 300,000 compounds a day, is designed to make drug discovery smarter, faster and cheaper. It can work three times more quickly than previous drug discovery robots and can sense and adapt to the presence of its human workmates. This means it can share their workspace without protective guarding.

Cancer Research UK, Cancer Research Technology and MRC Technology are joining forces to identify and validate novel drug discovery targets that could lead to new immunotherapy treatments